A Study of BBT001
Phase 1
198
about 1.9 years
18–65
1 site in NY
What this study is about
Researchers are testing a treatment called BBT001 in two groups: healthy volunteers and adults with atopic dermatitis. The trial will last for 709 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BBT001
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants with adverse events following single and multiple administration of BBT001
Secondary: Pharmacokinetics parameters- - Elimination Half-life (t1/2)., Pharmacokinetics parameters- Area under the curve (AUC), Pharmacokinetics parameters- Time for maximum observed Concentration (Tmax), Pharmacokinetics parameters- Total clearance (CL), Pharmacokinetics parameters- Volume of distribution (Vz), Pharmacokinetics parameters- maximum observed Concentration (Cmax)
Dermatology